JP5491631B2 - 肛門性器路の癌の早期診断方法 - Google Patents
肛門性器路の癌の早期診断方法 Download PDFInfo
- Publication number
- JP5491631B2 JP5491631B2 JP2012529163A JP2012529163A JP5491631B2 JP 5491631 B2 JP5491631 B2 JP 5491631B2 JP 2012529163 A JP2012529163 A JP 2012529163A JP 2012529163 A JP2012529163 A JP 2012529163A JP 5491631 B2 JP5491631 B2 JP 5491631B2
- Authority
- JP
- Japan
- Prior art keywords
- methylation
- cancer
- znf671
- astn1
- hpv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 30
- 201000011510 cancer Diseases 0.000 title claims description 29
- 238000013399 early diagnosis Methods 0.000 title description 3
- 230000011987 methylation Effects 0.000 claims description 67
- 238000007069 methylation reaction Methods 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 61
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 239000000523 sample Substances 0.000 claims description 40
- 102100028943 Zinc finger protein 671 Human genes 0.000 claims description 27
- 108020004414 DNA Proteins 0.000 claims description 25
- 238000009595 pap smear Methods 0.000 claims description 25
- 101000936741 Homo sapiens Astrotactin-1 Proteins 0.000 claims description 24
- 101000915607 Homo sapiens Zinc finger protein 671 Proteins 0.000 claims description 24
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 23
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 23
- 201000010881 cervical cancer Diseases 0.000 claims description 23
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims description 22
- 102100027708 Astrotactin-1 Human genes 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 20
- 238000007855 methylation-specific PCR Methods 0.000 claims description 13
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 8
- 108091023040 Transcription factor Proteins 0.000 claims description 8
- 102000040945 Transcription factor Human genes 0.000 claims description 8
- 101710120624 Astrotactin-1 Proteins 0.000 claims description 6
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 4
- 101710180773 Zinc finger protein 671 Proteins 0.000 claims description 4
- 238000007399 DNA isolation Methods 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- 230000004544 DNA amplification Effects 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000013615 primer Substances 0.000 description 29
- 101150005988 cin2 gene Proteins 0.000 description 21
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 15
- 102100022105 Relaxin-3 receptor 1 Human genes 0.000 description 11
- 101710117864 Relaxin-3 receptor 1 Proteins 0.000 description 11
- 239000007850 fluorescent dye Substances 0.000 description 11
- 239000003550 marker Substances 0.000 description 9
- 101150070189 CIN3 gene Proteins 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 8
- 230000007067 DNA methylation Effects 0.000 description 8
- 101000864690 Homo sapiens Homeobox protein DLX-1 Proteins 0.000 description 8
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 8
- 102100032818 Integrin alpha-4 Human genes 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 108091029523 CpG island Proteins 0.000 description 5
- 102100030087 Homeobox protein DLX-1 Human genes 0.000 description 5
- 229940104302 cytosine Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 108010049959 Discoidins Proteins 0.000 description 4
- 206010058314 Dysplasia Diseases 0.000 description 4
- -1 EDIL3 Proteins 0.000 description 4
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 4
- 108010041012 Integrin alpha4 Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 241000239226 Scorpiones Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 208000009458 Carcinoma in Situ Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000004933 in situ carcinoma Diseases 0.000 description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108090000103 Relaxin Proteins 0.000 description 2
- 102000003743 Relaxin Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000006607 hypermethylation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 108010011903 peptide receptors Proteins 0.000 description 2
- 102000014187 peptide receptors Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101150061050 CIN1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101100436269 Homo sapiens ASTN1 gene Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 108060004056 Integrin alpha Chain Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100034944 Relaxin-3 Human genes 0.000 description 1
- 101710113452 Relaxin-3 Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 101150042526 ZNF671 gene Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004745 cervical carcinogenesis Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 102000017777 integrin alpha chain Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09011941A EP2308998A1 (de) | 2009-09-18 | 2009-09-18 | Verfahren zur frühen Diagnose von Karzinomen des Anogenitaltraktes |
| EP09011941.3 | 2009-09-18 | ||
| PCT/EP2010/005735 WO2011032721A1 (de) | 2009-09-18 | 2010-09-17 | Verfahren zur frühen diagnose von karzinomen des anogenitaltraktes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013505007A JP2013505007A (ja) | 2013-02-14 |
| JP2013505007A5 JP2013505007A5 (enExample) | 2013-10-03 |
| JP5491631B2 true JP5491631B2 (ja) | 2014-05-14 |
Family
ID=41564137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529163A Active JP5491631B2 (ja) | 2009-09-18 | 2010-09-17 | 肛門性器路の癌の早期診断方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8575326B2 (enExample) |
| EP (2) | EP2308998A1 (enExample) |
| JP (1) | JP5491631B2 (enExample) |
| CA (1) | CA2774458C (enExample) |
| DK (1) | DK2478117T3 (enExample) |
| ES (1) | ES2431301T3 (enExample) |
| WO (1) | WO2011032721A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102082099B1 (ko) * | 2012-05-11 | 2020-02-26 | 국립연구개발법인 고쿠리츠간켄큐센터 | 신장 세포암의 예후 예측방법 |
| CN104513851B (zh) * | 2013-10-08 | 2017-01-11 | 陈永恩 | 侦测膀胱癌的新颖表基因生物标记及其方法 |
| DE102015101555A1 (de) * | 2015-02-03 | 2016-08-04 | Oncgnostics GmbH BioInstrumentezentrum Jena | Verfahren und Kit zur Bestimmung des Risikos einer Entwicklung eines Zervixkarzinoms oder einer seiner malignen Vorstufen |
| AU2017433280B2 (en) * | 2017-09-29 | 2025-03-06 | Oncgnostics Gmbh | Risk determination for neoplasia and cancer |
| CN107760788B (zh) * | 2017-12-05 | 2021-03-02 | 武汉艾米森生命科技有限公司 | 一种检测宫颈细胞基因甲基化的核酸组合及试剂盒与应用 |
| AU2020211461A1 (en) * | 2019-01-24 | 2021-08-19 | Exact Sciences Corporation | Detecting endometrial cancer |
| CN110452984A (zh) * | 2019-07-29 | 2019-11-15 | 韩林志 | 一种用于宫颈癌甲基化检测的甲基化基因组合、引物和探针组合、试剂盒及其使用方法 |
| JP2022553575A (ja) | 2019-10-31 | 2022-12-23 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 卵巣癌の検出 |
| CA3162799A1 (en) * | 2019-12-23 | 2021-07-01 | Benjamin F. DELATTE | Methods and kits for the enrichment and detection of dna and rna modifications and functional motifs |
| EP4298249A1 (en) | 2021-02-26 | 2024-01-03 | Oncgnostics GmbH | Diagnosis and risk determination for head and neck cancer |
| CN112941189B (zh) * | 2021-05-06 | 2023-07-21 | 中南大学 | 宫颈癌早筛分子标志物znf671基因甲基化检测的引物探针组合物及试剂盒和使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10019058A1 (de) * | 2000-04-06 | 2001-12-20 | Epigenomics Ag | Detektion von Variationen des DNA-Methylierungsprofils |
| WO2005020784A2 (en) * | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
-
2009
- 2009-09-18 EP EP09011941A patent/EP2308998A1/de not_active Withdrawn
-
2010
- 2010-09-17 JP JP2012529163A patent/JP5491631B2/ja active Active
- 2010-09-17 DK DK10765749.6T patent/DK2478117T3/da active
- 2010-09-17 WO PCT/EP2010/005735 patent/WO2011032721A1/de not_active Ceased
- 2010-09-17 EP EP10765749.6A patent/EP2478117B1/de active Active
- 2010-09-17 ES ES10765749T patent/ES2431301T3/es active Active
- 2010-09-17 US US13/496,812 patent/US8575326B2/en active Active
- 2010-09-17 CA CA2774458A patent/CA2774458C/en active Active
-
2013
- 2013-08-29 US US14/013,272 patent/US9228238B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011032721A1 (de) | 2011-03-24 |
| EP2308998A1 (de) | 2011-04-13 |
| ES2431301T3 (es) | 2013-11-25 |
| JP2013505007A (ja) | 2013-02-14 |
| US20130344479A1 (en) | 2013-12-26 |
| US8575326B2 (en) | 2013-11-05 |
| EP2478117B1 (de) | 2013-07-31 |
| US9228238B2 (en) | 2016-01-05 |
| US20120208180A1 (en) | 2012-08-16 |
| DK2478117T3 (da) | 2013-10-28 |
| CA2774458C (en) | 2021-04-27 |
| EP2478117A1 (de) | 2012-07-25 |
| CA2774458A1 (en) | 2011-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5491631B2 (ja) | 肛門性器路の癌の早期診断方法 | |
| JP6369857B2 (ja) | 肝細胞癌に関する情報の取得方法、ならびに肝細胞癌に関する情報を取得するためのマーカーおよびキット | |
| US20150361502A1 (en) | Method for screening cancer | |
| JP6381020B2 (ja) | 大腸癌に関する情報の取得方法、ならびに大腸癌に関する情報を取得するためのマーカーおよびキット | |
| WO2010118559A1 (zh) | 一种癌症筛检的方法 | |
| JP2009106191A (ja) | 肝臓癌関連遺伝子、及び肝臓癌リスクの判定方法 | |
| CN107475443A (zh) | 子宫颈癌检测套组 | |
| CN116144782A (zh) | 一种用于肺癌检测的组合标志物及其应用 | |
| CN108949923B (zh) | 一种扩增msf1基因的方法及试剂盒与应用 | |
| EP3162899A1 (en) | Biomarker for breast cancer | |
| KR102492149B1 (ko) | 난소암 진단 또는 감별진단을 위한 마이크로rna-1246 및 이의 용도 | |
| JP5602355B2 (ja) | 癌患者の外科的手術後の治療選択方法及び予後診断 | |
| CN116356027B (zh) | 一种用于食管鳞癌或癌前病变检测的试剂、试剂盒及应用 | |
| CN116024342B (zh) | 用于检测宫颈癌或癌前病变的核酸产品、试剂盒及应用 | |
| CN116121387A (zh) | 一种用于结直肠癌检测的组合标志物及其应用 | |
| KR20220052462A (ko) | 난소암 진단 또는 감별진단을 위한 마이크로rna-1290 및 이의 용도 | |
| CN116162707B (zh) | 检测cyth2基因或/和six3基因中的目标区域的甲基化水平的试剂的新应用 | |
| CN114196755B (zh) | 用于诊断受试者宫颈病变的组合物及用途 | |
| CN118792405A (zh) | 一种诊断宫颈癌的甲基化标志物组合及其应用 | |
| CN120464734A (zh) | 用于检测卵巢癌的组合物及其用途 | |
| AU2023408532A1 (en) | Methylation marker for cancer | |
| WO2024204603A1 (ja) | 膀胱癌のバイオマーカー | |
| CN120330333A (zh) | 用于体外检测子宫内膜癌的甲基化标志物ocel1基因、olig2基因及其用途 | |
| CN118581218A (zh) | 用于hpv阴性宫颈癌检测的核酸产品、试剂盒及应用 | |
| CN117187388A (zh) | Grik2基因作为标志物在制备肺癌检测试剂盒中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130819 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130819 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20130819 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20131002 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131015 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140106 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140204 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140227 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5491631 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |